Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Grace provides Acasti with a pipeline of rare and orphan disease programs. Grace's GTX-104 is a Novel aqueous nanoparticle formulation of water insoluble nimodipine, is believed to potentially improve the management of hypotension and vasospasm in SAH patients.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Product Name: GTX-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acasti Pharma
Deal Size: $64.0 million Upfront Cash: $64.0 million
Deal Type: Acquisition May 07, 2021